Maja Dembic

Maja Dembic

Auto-generated profile, based on publicly available information

Maja Dembic

Odense University Hospital

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
TDThomas Koed Doktor
Thomas Koed Doktor
YHYimin Hua
Yimin Hua
HAHenriette Skovgaard Andersen
Henriette Skovgaard Andersen
SBSabrina Brøner
Sabrina Brøner
YLYing Hsiu Liu
Ying Hsiu Liu
BABrage Storstein Andresen
Brage Storstein Andresen
Spinal Muscular Atrophy (SMA) is a neuromuscular disorder caused by insufficient levels of the Survival of Motor Neuron (SMN) protein. SMN is expressed ubiquitously and functions in RNA processing pathways that include trafficking of mRNA and assembly of snRNP complexes. Importantly, SMA severity is correlated with decreased snRNP assembly activity. In particular, the minor spliceosomal snRNPs are affected, and some U12-dependent introns have been reported to be aberrantly spliced in patient cells and animal models. SMA is characterized by loss of motor neurons, but the underlying mechanism is largely unknown. It is likely that aberrant splicing of genes expressed in motor neurons is involved in SMA pathogenesis, but increasing evidence indicates that pathologies also exist in other tissues. We present here a comprehensive RNA-seq study that covers multiple tissues in an SMA mouse model. We show elevated U12-intron retention in all examined tissues from SMA mice, and that U12-dependent intron retention is induced upon siRNA knock-down of SMN in HeLa cells. Furthermore, we show that retention of U12-dependent introns is mitigated by ASO treatment of SMA mice and that many transcriptional changes are reversed. Finally, we report on missplicing of several Ca2+ channel genes that may explain disrupted Ca2+ homeostasis in SMA and activation of Cdk5.

1 December 2017 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
SMSigne Mosegaard
Signe Mosegaard
GBGitte Hoffmann Bruun
Gitte Hoffmann Bruun
KFKaren Freund Flyvbjerg
Karen Freund Flyvbjerg
YBYngve Thomas Bliksrud
Yngve Thomas Bliksrud
NGNiels Gregersen
Niels Gregersen
BABrage Storstein Andresen
Brage Storstein Andresen

1 November 2016 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
BPBruno Palhais
Bruno Palhais
MDMaja Dembic
Maja Dembic
RSRugivan Sabaratnam
Rugivan Sabaratnam
KNKira S. Nielsen
Kira S. Nielsen
TDThomas Koed Doktor
Thomas Koed Doktor
BABrage Storstein Andresen
Brage Storstein Andresen

1 October 2013 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Closed access
PHPaula L. Hedley
Paula L. Hedley
JKJørgen Kanters
Jørgen Kanters
MDMaja Dembic
Maja Dembic
TJThomas Jespersen
Thomas Jespersen
LSLasse Skibsbye
Lasse Skibsbye
MCMichael Christiansen
Michael Christiansen
Background—: Mutations in CAV3 , coding for caveolin-3, the major constituent scaffolding protein of cardiac caveolae, have been associated with skeletal muscle disease, cardiomyopathy, and most recently long–QT syndrome (LQTS) and sudden infant death syndrome. We examined the occurrence of CAV3 mutations in a large cohort of patients with LQTS. Methods and Results—: Probands with LQTS (n=167) were screened for mutations in CAV3 using direct DNA sequencing. A single proband (0.6%) was found to be a heterozygous carrier of a previously described missense mutation, caveolin-3:p.T78M. The proband was also a heterozygous carrier of the trafficking-deficient Kv11.1:p.I400N mutation. The caveolin-3:p.T78M mutation was found isolated in 3 family members, none of whom had a prolonged QT c interval. Coimmunoprecipitations of caveolin-3 and the voltage-gated potassium channel subunit (Kv11.1) were performed, and the electrophysiological classification of the Kv11.1 mutant was carried out by patch-clamp technique in human embryonic kidney 293 cells. Furthermore, the T-wave morphology was assessed in mutation carriers, double mutation carriers, and nonmutation carriers by applying a morphology combination score. The morphology combination score was normal for isolated caveolin-3:p.T78M carriers and of LQT2 type in double heterozygotes. Conclusions—: Mutations in CAV3 are rare in LQTS. Furthermore, caveolin-3:p.T78M did not exhibit a LQTS phenotype. Because no association has ever been found between LQTS and isolated CAV3 mutations, we suggest that LQTS9 is considered a provisional entity.

23 April 2018 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
AMAinhoa Martínez-Pizarro
Ainhoa Martínez-Pizarro
MDMaja Dembic
Maja Dembic
BPBelen Perez
Belen Perez
BABrage Storstein Andresen
Brage Storstein Andresen
LDLourdes Desviat
Lourdes Desviat
Phenylketonuria (PKU), one of the most common inherited diseases of amino acid metabolism, is caused by mutations in the phenylalanine hydroxylase (PAH) gene. Recently, PAH exon 11 was identified as a vulnerable exon due to a weak 3’ splice site, with different exonic mutations affecting exon 11 splicing through disruption of exonic splicing regulatory elements. In this study, we report a novel intron 11 regulatory element, which is involved in exon 11 splicing, as revealed by the investigated pathogenic effect of variants c.1199+17G>A and c.1199+20G>C, identified in PKU patients. Both mutations cause exon 11 skipping in a minigene system. RNA binding assays indicate that binding of U1snRNP70 to this intronic region is disrupted, concomitant with a slightly increased binding of inhibitors hnRNPA1/2. We have investigated the effect of deletions and point mutations, as well as overexpression of adapted U1snRNA to show that this splicing regulatory motif is important for regulation of correct splicing at the natural 5’ splice site. The results indicate that U1snRNP binding downstream of the natural 5’ splice site determines efficient exon 11 splicing, thus providing a basis for development of therapeutic strategies to correct PAH exon 11 splicing mutations. In this work, we expand the functional effects of non-canonical intronic U1 snRNP binding by showing that it may enhance exon definition and that, consequently, intronic mutations may cause exon skipping by a novel mechanism, where they disrupt stimulatory U1 snRNP binding close to the 5’ splice site. Notably, our results provide further understanding of the reported therapeutic effect of exon specific U1 snRNA for splicing mutations in disease. Splicing defects constitute a major cause of human disease. Mutations affecting conserved splicing sequences at exon-intron junctions are easily recognized as possibly pathogenic, whereas variants in exonic or intronic regions are difficult to classify without functional evidence provided by transcript analysis or in vitro analysis using minigenes. In this work, we sought out to study the pathogenicity of two novel intronic PAH variants identified in phenylketonuria patients. Both mutations resulted in exon skipping in minigenes. We demonstrate that U1snRNP70 binds to the intronic region and that this binding is abolished in the mutant sequences. Correction of the splicing defect was achieved using modified U1 snRNA perfectly complementary to each of the mutant sequences. The results extend the repertoire of natural U1 snRNP cellular functions by including its role as splicing enhancer via binding downstream of the natural 5’ splice site. In addition, our results correlate with the described therapeutic effect of modified U1snRNP for splicing mutations in different genes, thus having a significant impact in the development of specific therapies for splicing defects.

4 September 2007 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
ECElena Cipollini
Elena Cipollini
MRMassimo Riccio
Massimo Riccio
RGRossella Di Giaimo
Rossella Di Giaimo
FPFabrizio Dal Piaz
Fabrizio Dal Piaz
GPGiuseppe Pulice
Giuseppe Pulice
MMMarialuisa Melli
Marialuisa Melli